CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
US11407721B2 · kind B2 · utility
0Cited by
24References
46Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 30, 2018 |
| Grant date | Aug 9, 2022 |
| Priority date | — |
| Expiry date | Jul 30, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.